Table 2.

Active phase III clinical trials concerning dendritic cell vaccination as adjuvant treatment in various malignancies (as of May 2018).

Disease	Vaccine formulation	Status	Identifier
Melanoma (stage III)	Natural dendritic cell subsets loaded with melanoma-specific peptides	Recruiting	NCT02993315
Uveal melanoma (high risk)	Dendritic cells loaded with autologous tumor RNA	Recruiting	NCT01983748
Glioblastoma (newly diagnosed)	DCVax®-L: dendritic cells loaded with tumor lysate	Active, not recruiting	NCT00045968